Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Inclusion Criteria: * Provide written informed consent * Subjects age \> 21 and \< 95 years at the time of signing the Informed Consent Form. * Each subject must have endothelial dysfunction. Endothelial dysfunction Criteria: Impaired flow-mediated vasodilation (FMD \<7%) • At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following: * Waist circumference - US defined: ≥ 102 cm (males) or ≥ 88 cm (females) * Elevated triglycerides - ≥ 150 mg/dL (1.7 mM) * Reduced HDL-C - Males: \<40 mg/dL (1.0 mM) Females: \<50 mg/dL (1.3 mM) * Elevated blood pressure - Systolic ≥ 130 mm Hg and/or Diastolic ≥ 85 mm Hg * Elevated fasting glucose - ≥ 100 mg/dL Exclusion Criteria: * Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion. * Inability to perform any of the assessments required for endpoint analysis. * Active listing (or expected future listing) for transplant of any organ. * Clinically important abnormal screening laboratory values, as determined by the P.I. * Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study. * Have known allergies to penicillin or streptomycin. * Hypersensitivity to dimethyl sulfoxide (DMSO). * Be a solid organ transplant recipient. This does not include prior cell-based therapy (\>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection. * Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs. * Have a non-pulmonary condition that limits lifespan to \< 1 year. * History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months. * Be serum positive for HIV, hepatitis B surface antigen or Viremic hepatitis C, and/or Syphilis. * Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. * Patients with Ejection Fraction \<45% (heart failure patients). * Glomerular Filtration Rate \< or equal to 35 (chronic kidney disease stage 3 or higher). * Liver disease (elevated Liver Function Tests greater than 3x normal limit). * Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span). * Proliferative diabetic retinopathy * Hemoglobin A1C greater than 7.